Panacea Biotec wins UNICEF vaccine order worth US$35.65 million

Export Order Hard CurrencyBusiness Updates View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹400.00

prior close

₹399.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+2.3% vs market

Pharmaceuticals peers, median of 151sector+0.2%+3.4% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.8

10m

+4.5

15m

+3.2

30m

+3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6+1.3+2.3+0.2+3.4

Next day

+6.6+1.0+5.6+0.0+6.6

+7.6+0.8+6.8-0.3+7.9

+7.3+0.5+6.8-0.9+8.2

+9.8+0.7+9.0-0.4+10.2

+8.6+1.4+7.2-0.1+8.7

+10.8-0.3+11.0-1.2+11.9

15d

+9.3+2.4+7.0-0.7+10.0

+8.3+3.6+4.6+0.4+7.9

-12.3-1.6-10.6-3.7-8.6

-7.8-1.5-6.3-5.0-2.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec received a Letter of Award from UNICEF to supply bivalent oral polio vaccine in 10-vial and 20-vial packs. The award is worth about US$35.65 million, or about Rs 315 crore, and covers Q2 CY2026 and CY2027 within a long-term agreement running from April 2026 to March 2030.

Likely market impact

Supports future export sales and earnings from a major international vaccine contract, though deliveries start in 2026 and remain subject to conditions.